Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Lung Neoplasms 22Breast Neoplasms 18Hematologic Neoplasms 17Colorectal Neoplasms 13Prostatic Neoplasms 11Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Pancreatic Neoplasms 9Hematopoietic and Lymphatic System Neoplasm 8Anatomic Stage I Breast Cancer AJCC v8 8Urinary Bladder Neoplasms 6Ovarian Neoplasms 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Multiple Myeloma 5Melanoma 5Head and Neck Carcinoma 5Breast Carcinoma In Situ 5Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Hematopoietic and Lymphoid System Neoplasm 4Mouth Neoplasms 3Lymphoma 3Leukemia, Myeloid, Acute 3Head and Neck Neoplasms 3Esophageal Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Carcinoma 3

Interventions

Temozolomide 64Radiotherapy 53Filgrastim 28Carboplatin 24Etoposide 20Irinotecan 17Vincristine 16Cyclophosphamide 16Cisplatin 15Carmustine 14Peripheral Blood Stem Cell Transplantation 13Magnetic Resonance Spectroscopy 12Bevacizumab 12Thiotepa 11Thalidomide 11Chemotherapy, Adjuvant 11Methotrexate 10Paclitaxel 9Granulocyte Colony-Stimulating Factor 9etoposide phosphate 8Surgical Procedures, Operative 8Procarbazine 8Ifosfamide 8sargramostim 7Topotecan 7O(6)-benzylguanine 7Lomustine 7Busulfan 7Radiation 6Melphalan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Central Nervous System Neoplasms × Practice Guidelines as Topic × Clear all
NCT05720624 2025-10-22

Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation

Mayo Clinic

Phase 1 Withdrawn
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡